-
ArticlePublication 2008Community and Patient Values for Preventing Herpes Zoster
In this 2008 article, the authors report on a survey to assess the value individuals …
In this 2008 article, the authors report on a survey to assess the value individuals place on preventing herpes zoster. The Zoster Vaccine Live (ZVL) was recommended for routine use in adults aged ≥60 years. Members of the population (“community members”, n= 527), patients with shingles (n= 382) or post-herpetic neuralgia (PHN, n = 137) completed an internet or telephone survey to assess the value they place on preventing herpes zoster. The authors used standard…
Preferences/Values | North America | Health Outcomes | Culture/Society | Health/Medicine -
ArticlePublication 2007Measuring Health Preferences for Use in Analyses of Interventions in Children
Valuing the health of children for cost-utility or cost-benefit analysis is more challenging than valuing …
Valuing the health of children for cost-utility or cost-benefit analysis is more challenging than valuing adult health. Young children cannot conceptualize value, they are not responsible for their own decision making, and proxies may not fully understand the child perspective. Moreover illness in children may affect parent/caregiver health and quality of life, further complicating the measurement of value associated with a change in a child’s health status.This paper reviews the most common approaches (QALYs and willingness-to-pay)…
Preferences/Values | North America | Health Outcomes | Infectious Diseases | Child/Nutrition | Europe -
ArticlePublication 2008Potential Cost-Effectiveness of Vaccination against Herpes Zoster and Post-Herpetic Neuralgia
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine …
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine against herpes zoster (HZ) and post-herpetic neuralgia (PHN). The authors used a cohort model to estimate the burden of HZ and the cost-effectiveness of HZ vaccination from a ministry of health perspective using Canadian population-based data. They examined different ages at vaccination and conducted probabilistic sensitivity analysis.There are about 130,000 new cases of HZ, 17,000 cases of PHN and 20 deaths…
Preferences/Values | North America | Dynamic Transmission | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ReviewPublication 2013Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies …
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies Most studies evaluated the cost effectiveness of universal HZ vaccination in adults aged 50 years or 60 years and older and all studies calculated costs per QALY. The costs per QALY gained and the incremental cost-effectiveness ratio (ICER) differed depending on the age at vaccination, duration of vaccine efficacy, cost of vaccine course, and economic perspective. All but one of…
Preferences/Values | North America | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Economics/Finance | Health/Medicine
4 Shown
Teaching Resources
Collections
Format
Learner Level
Teaching Topic